Molecular Partners announced it will present clinical data on its lead Radio-DARPin candidate MP0712, targeting DLL3 in small cell lung cancer (SCLC), at the 2026 SNMMI Theranostics Conference and the NACLC 2026. MP0712 is in a Phase 1/2a study and shows promise as a novel targeted radiotherapeutic for SCLC and other DLL3-expressing tumors. The presentations will share initial dose escalation and safety data, highlighting progress in this innovative cancer treatment approach. These updates are significant for advancing new therapies for cancers with limited treatment options.
Molecular Partners' upcoming presentations on the Radio-DARPin MP0712 provide context for the health sector's performance on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 13:11 WIB: out of 150 priced US health-sector stocks, 116 rose and 32 fell. Notable movers include ACHC at USD 34.05 with a 14.96% increase but 89% sell order activity, ZBH at USD 110.15 up 13.49% with 91% buy orders, and CNC at USD 76.21 rising 12.94% with 100% buy orders. Typical hold times range from 9 to 90 days on Pluang.
Siemens Healthineers has begun separating its in vitro diagnostics business into a standalone company named Olyrian Diagnostics, expected to complete by mid-2028. This move aims to give the diagnostics unit a distinct market presence while continuing...
IQM Quantum Computers reported a 52% increase in order backlog to €102.5 million by September 30, 2026, driven by major new contracts including the LUMI-IQ Halocene order. Q3 revenue rose 51% year-over-year to €8.9 million, with cash reserves at €260...
IQM Quantum Computers reported a 52% increase in order backlog to EUR 102.5 million by September 2026, driven by strong new orders including a EUR 33 million contract for its error-correction platform. Q3 revenue rose 51% year-over-year to EUR 8.9 mi...
Financial institutions are increasingly deploying multi-agent AI systems to enhance banking and insurance workflows, with 59% piloting or deploying such systems. However, only 10% have achieved full enterprise-wide orchestration, highlighting challen...
Ademi LLP is investigating ServiceTitan for potential securities fraud related to alleged inaccurate statements about its financials and the rollout of its AI product, Max. This inquiry follows a drop in ServiceTitan's stock price and concerns about ...
